false
0001377121
0001377121
2024-02-27
2024-02-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d)
of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported): February 27, 2024
PROTAGONIST THERAPEUTICS, INC.
(Exact name of registrant as specified
in its charter)
Delaware |
|
001-37852 |
|
98-0505495 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
Protagonist Therapeutics, Inc.
7707 Gateway Blvd., Suite 140
Newark, California 94560-1160
(Address of principal executive offices,
including zip code)
(510) 474-0170
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which
registered |
Common Stock, par value $0.00001 |
|
PTGX |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations
and Financial Condition.
On February 27, 2024, Protagonist
Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2023. A copy of the
press release titled “Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update”
is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits
The information in this report, including the exhibit hereto, shall
not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein
and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission
made by Protagonist Therapeutics, Inc., whether made before or after the date hereof, regardless of any general incorporation language
in such filing.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Protagonist Therapeutics, Inc. |
|
|
Dated: February 27, 2024 |
|
|
|
|
By: |
/s/ Asif Ali |
|
Asif Ali |
|
|
Chief Financial Officer |
Exhibit 99.1
Protagonist Reports
Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Worldwide
collaboration agreement executed with Takeda Pharmaceuticals, including a $300 million upfront
payment for rusfertide in polycythemia vera and other hematological indications
Cash runway extended
through Q4 20271
Two articles
published in the New England Journal of Medicine reporting results from the Phase 2b FRONTIER 1 study of JNJ-2113 and the Phase 2 REVIVE
study of rusfertide
Our Partner,
Johnson & Johnson Innovative Medicine (formerly Janssen) initiated an expanded JNJ-2113 clinical development program with four
Phase 3 studies in moderate-to-severe psoriasis and one Phase 2b study in moderately-to-severely active ulcerative colitis
Protagonist achieved
$60 million in milestones in Q4 related to JNJ-2113
NEWARK,
Calif., February 27, 2024 – Protagonist
Therapeutics (Nasdaq: PTGX) (“Protagonist” or “the Company”) today reported financial results for the fourth
quarter and full year ended December 31, 2023, and provided a corporate update.
“The
fourth quarter of 2023 was an extremely busy and productive time for Protagonist,” said Dinesh V. Patel, Ph.D., the Company’s
President and CEO. “Our novel hepcidin mimetic rusfertide was well represented at the American Society of Hematology (ASH) Annual
Meeting in December, including an oral presentation of the long-term follow-up data from the Phase 2 REVIVE study showing durability
of hematocrit control and no new safety signals. We look forward to completing enrollment of the Phase 3 VERIFY study by the end of Q1
2024, and potentially filing an NDA next year after completion of the 52-week study. We are extremely pleased to have joined hands with
our new partner Takeda in preparation for the potential commercial launch of rusfertide.”
Dr. Patel continued: “The
JNJ-2113 clinical development program is progressing and expanding in a very impressive way, with four Phase 3 psoriasis studies and
a Phase 2b study in ulcerative colitis. We believe that JNJ-2113 has the potential to be a major part of the Inflammation &
Immunology franchise. Internally, we continue to expand our discovery efforts and are evaluating novel oral peptides against validated
biological pathways with the aim of achieving major differentiation against the current standards of care and addressing significant
unmet needs in various disease indications. In drug discovery, we plan to announce an oral peptide IL-17 development candidate by year
end, maximizing our presence with first-in-class drug candidates for diseases mediated by the IL-17/IL-23 pathway.”
1 Based on Cash, Cash Equivalents and Marketable Securities
as of December 31, 2023, and including the $300m upfront payment expected from the worldwide collaboration agreement with Takeda Pharmaceuticals,
but excluding all future milestones, including those expected with respect to JNJ-2113.
Fourth
Quarter 2023 Recent Developments and Upcoming Milestones
Rusfertide:
Subcutaneous Injectable Hepcidin Mimetic for Polycythemia Vera (PV) and Other Blood
Disorders
| · | On
January 31, 2024, Takeda and Protagonist Therapeutics, Inc.
announced that they had entered into a worldwide license and collaboration agreement for
rusfertide. Under the terms of the agreement, Protagonist will receive an upfront payment
of $300 million and is eligible to receive additional worldwide development, regulatory milestone
and commercial milestones as well as tiered royalties on ex-U.S. net sales. Protagonist and
Takeda will share equally in all operating profits and losses arising from the commercialization
of rusfertide in the U.S. (“profit and loss sharing arrangement”). Protagonist
remains responsible for research and development through the completion of the Phase VERIFY
3 clinical trial, as well as for U.S. regulatory filings. Takeda has rights for ex-U.S. development
and is responsible for leading global commercialization activities. |
| · | The
Company also has the right to opt-out entirely from the profit and loss sharing arrangement
in exchange for opt-out payments of up to $400 million and enhanced milestones and worldwide
royalties. |
| · | Five
abstracts related to rusfertide were presented at the
American Society of Hematology conference in December 2023. These presentations included: |
| o | Long
term follow-up from the REVIVE Phase 2 study which showed durable hematocrit control, decreased
phlebotomy use, long-term tolerability, and no new safety signals in patients with PV. |
| o | Prevalence
of thromboembolic events (TEs) and secondary cancers in polycythemia vera based on a retrospective
analysis of real-world claims data from a large US electronic health records database of
patients not treated with rusfertide. These studies showed that PV patients experience high
rates of arterial and venous TEs and increased risk of developing other cancers, particularly
after exposure to hydroxyurea. |
| · | On
February 21, 2024, the complete Phase 2 REVIVE trial results, including efficacy and
safety, were published in the New England Journal of Medicine. |
| · | Enrollment
in Phase 3 VERIFY trial remains on track for completion by the end of Q1 2024. |
JNJ-2113
(formerly PN-235): Oral IL-23 Receptor Antagonist
| · | Protagonist
earned $60.0 million in the fourth quarter of 2023 for milestones achieved in the JNJ-2113
Phase 2b and Phase 3 clinical programs led by the Company's
collaboration partner, J&J Innovative Medicines. These milestones comprised of
(i) $50 million earned when the third patient was dosed in the ICONIC TOTAL Phase 3
clinical study of JNJ-2113 in patients with moderate-to-severe psoriasis and (ii) $10
million following the dosing of the third patient in ANTHEM-UC, a Phase 2b trial to
evaluate the safety and effectiveness of JNJ-2113 compared with placebo in patients with
moderately to severely active ulcerative colitis. |
| · | On
February 7, 2024, the JNJ-2113 Phase
2b FRONTIER 1 trial results in adults living with moderate-to-severe plaque psoriasis were
published in the New England Journal of Medicine. |
| · | The
pivotal Phase 3 ICONIC clinical development program of JNJ-2113 in adult and adolescent patients
with moderate-to-severe plaque psoriasis was initiated with two studies in Q4 2023 –
ICONIC-LEAD and ICONIC-TOTAL. Other Phase 3 studies in the development program are expected
to begin in Q1 2024, including ICONIC ADVANCE 1 and ICONIC ADVANCE 2, which will evaluate
the safety and efficacy of JNJ-2113 compared with both placebo and deucravacitinib. |
| · | The
Phase 2b multicenter, randomized,
placebo- controlled, dose-ranging study of JNJ-2113 for the treatment of moderately to severely
active ulcerative colitis continues to enroll, with an
estimated completion date of Q2 2025. |
Discovery
Programs
| · | Protagonist
announced an oral IL-17 discovery
program in January 2024 with
a development candidate expected later in 2024, and the company is pursuing the discovery
of novel oral peptides against various clinically validated biological targets in hematology,
inflammation and immunomodulatory and metabolic diseases. |
Fourth Quarter 2023 Financial Results
| · | Cash,
Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities
as of December 31, 2023, were $341.6 million as compared to $237.4 million in the previous
year. |
| |
Three Months Ended | | |
Twelve Months Ended | |
| |
December 31, | | |
December 31, | |
(in thousands, except per share amounts) | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
License and collaboration revenue | |
$ | 60,000 | | |
$ | - | | |
$ | 60,000 | | |
$ | 26,581 | |
Research and development expense | |
$ | 28,899 | | |
$ | 29,884 | | |
$ | 120,161 | | |
$ | 126,215 | |
General and administrative expense | |
$ | 8,052 | | |
$ | 6,632 | | |
$ | 33,491 | | |
$ | 31,739 | |
Net income (loss) | |
$ | 27,335 | | |
$ | (34,194 | ) | |
$ | (78,955 | ) | |
$ | (127,393 | ) |
Basic earnings (loss) per share | |
$ | 0.45 | | |
$ | (0.69 | ) | |
$ | (1.39 | ) | |
$ | (2.60 | ) |
Diluted earnings (loss) per share | |
$ | 0.44 | | |
$ | (0.69 | ) | |
$ | (1.39 | ) | |
$ | (2.60 | ) |
| · | License
and Collaboration Revenue: License and collaboration revenue of $60 million for both
the fourth quarter and full year of 2023 was comprised of (i) $50 million earned when
the third patient was dosed in the ICONIC TOTAL Phase 3 clinical study of JNJ-2113 in patients
with moderate-to-severe psoriasis and (ii) $10 million following the dosing of the third
patient in ANTHEM-UC, a Phase 2b trial to evaluate the safety and effectiveness of JNJ-2113
compared with placebo in participants with moderately to severely active ulcerative colitis. The
full year 2022 results included a one-time $25.0 million milestone earned by the Company
following the dosing of the third patient in the JNJ Phase 2b FRONTIER 1 clinical trial of
JNJ-2113. |
| · | Research
and Development ("R&D") Expenses: The decrease in R&D expenses from
the prior year quarter was primarily due to a decrease in PN-943 expenses, partially offset
by an increase in rusfertide expenses related to the Phase 3 VERIFY clinical trial. The decrease
in R&D expense from the prior year was primarily due to decreases in PN-943 expenses
and costs related to preclinical and discovery research, partially offset by an increase
in rusfertide expenses. |
| · | General
and Administrative ("G&A") Expenses: The increase in G&A expenses from
the prior year quarter was primarily due to increases in payroll and stock-based compensation
and general expenses. The increase in G&A expenses from the prior year was primarily
due to increases in stock-based compensation, partially offset by one-time costs incurred
in the first quarter of 2022. |
| · | Net
Income (Loss): Net income was $27.3 million, or $0.45 per basic share and $0.44 per diluted
share, for the fourth quarter of 2023 as compared to a net loss of ($34.2) million, or ($0.69)
per basic and diluted share, for the fourth quarter of 2022. Net loss was ($79.0) million,
or ($1.39) per share, for the full year 2023, as compared to a net loss of $(127.4) million,
or ($2.60) per share, for the full year 2022. |
About Protagonist
Protagonist
Therapeutics is a biopharmaceutical company with peptide-based new chemical entities (NCEs) rusfertide and JNJ-2113 (formerly PN-235)
in advanced stages of clinical development, both derived from the Company's proprietary technology platform. Protagonist and JNJ scientists
jointly discovered PN-235 (now known as JNJ-2113) as part of Protagonist's Interleukin-23 receptor (IL-23R) collaboration with JNJ and
followed it through IND-enabling pre-clinical and Phase 1 studies, with JNJ assuming responsibility for further clinical development.
Rusfertide, a mimetic of the natural hormone hepcidin, is the Company's lead drug candidate currently in a global Phase 3 development
program. The randomized portion of the Phase 2 REVIVE study was unblinded, showing positive results
and is now complete, with an open-label extension underway. The global Phase 3 VERIFY study of rusfertide in polycythemia vera is ongoing.
Rusfertide will be co-developed
and co-commercialized with Takeda pursuant to a worldwide collaboration and license agreement with Takeda entered into in January 2024.
The agreement will be effective upon the termination or expiration of any applicable waiting periods under the Hart-Scott-Rodino Act.
More
information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at www.protagonist-inc.com.
Cautionary
Note on Forward-Looking Statements
This
press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Forward-looking statements include statements regarding the potential benefits of JNJ-2113, our expectations regarding the
timing of enrollment completion in our clinical trial (VERIFY), filing of the rusfertide NDA, clinical development of JNJ-2113 and our
ongoing IL-17 and other discovery research programs. In some cases, you can identify these statements by forward-looking words such as
"anticipate," "believe," "may," "will," "expect," or the negative or plural of these
words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties
that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to
develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreement with JNJ,
our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval
of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater
resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional
information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and
Exchange Commission, including under the heading "Risk Factors" contained in our most recently filed periodic reports on Form 10-K
and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance,
and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may
differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in
this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements,
whether as a result of new information, future events or otherwise, after the date of this press release.
Investor
Relations Contact
Corey
Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
Media Relations
Contact
Virginia
Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
+1 833 500 0061
PROTAGONIST THERAPEUTICS, INC.
Condensed Consolidated
Statements of Operations
(Amounts in thousands
except share and per share data)
| |
Three Months Ended | | |
Twelve Months Ended | |
| |
December 31, | | |
December 31, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
License and collaboration revenue | |
$ | 60,000 | | |
$ | - | | |
$ | 60,000 | | |
$ | 26,581 | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Research and development (1) | |
| 28,899 | | |
| 29,884 | | |
| 120,161 | | |
| 126,215 | |
General
and administrative (1) | |
| 8,052 | | |
| 6,632 | | |
| 33,491 | | |
| 31,739 | |
Total operating expenses | |
| 36,951 | | |
| 36,516 | | |
| 153,652 | | |
| 157,954 | |
Income (loss) from operations | |
| 23,049 | | |
| (36,516 | ) | |
| (93,652 | ) | |
| (131,373 | ) |
Interest income | |
| 4,242 | | |
| 2,251 | | |
| 14,898 | | |
| 4,060 | |
Other expense, net | |
| 44 | | |
| 71 | | |
| (201 | ) | |
| (80 | ) |
Net income (loss) | |
$ | 27,335 | | |
$ | (34,194 | ) | |
$ | (78,955 | ) | |
$ | (127,393 | ) |
Net income (loss) per share, basic | |
$ | 0.45 | | |
$ | (0.69 | ) | |
$ | (1.39 | ) | |
$ | (2.60 | ) |
Net income (loss) per share, diluted | |
$ | 0.44 | | |
$ | (0.69 | ) | |
$ | (1.39 | ) | |
$ | (2.60 | ) |
Weighted-average shares used to compute net income (loss) per
share, basic | |
| 60,387,606 | | |
| 49,252,633 | | |
| 56,763,559 | | |
| 49,042,232 | |
Weighted-average shares used to compute net income (loss) per
share, diluted | |
| 61,796,205 | | |
| 49,252,633 | | |
| 56,763,559 | | |
| 49,042,232 | |
| (1) | Amount
includes non-cash stock-based compensation expense. |
PROTAGONIST THERAPEUTICS, INC.
Stock-based Compensation
(In
thousands)
| |
Three Months Ended | | |
Twelve Months Ended | |
| |
December 31, | | |
December 31, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Research and development | |
$ | 3,890 | | |
$ | 3,429 | | |
$ | 17,061 | | |
$ | 14,719 | |
General and administrative | |
| 2,711 | | |
| 2,083 | | |
| 12,232 | | |
| 9,483 | |
Total stock-based compensation expense | |
$ | 6,601 | | |
$ | 5,512 | | |
$ | 29,293 | | |
$ | 24,202 | |
PROTAGONIST THERAPEUTICS, INC.
Selected Consolidated Balance Sheet Data
(In thousands)
| |
December 31, | | |
December 31, | |
| |
2023 | | |
2022 | |
Cash, cash equivalents and marketable securities | |
$ | 341,617 | | |
$ | 237,355 | |
Working capital | |
| 334,303 | | |
| 211,898 | |
Total assets | |
| 357,951 | | |
| 247,928 | |
Accumulated deficit | |
| (615,710 | ) | |
| (536,755 | ) |
Total stockholders' equity | |
| 336,677 | | |
| 215,608 | |
v3.24.0.1
Cover
|
Feb. 27, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Feb. 27, 2024
|
Entity File Number |
001-37852
|
Entity Registrant Name |
PROTAGONIST THERAPEUTICS, INC.
|
Entity Central Index Key |
0001377121
|
Entity Tax Identification Number |
98-0505495
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
7707 Gateway Blvd.
|
Entity Address, Address Line Two |
Suite 140
|
Entity Address, City or Town |
Newark
|
Entity Address, State or Province |
CA
|
Entity Address, Postal Zip Code |
94560-1160
|
City Area Code |
510
|
Local Phone Number |
474-0170
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, par value $0.00001
|
Trading Symbol |
PTGX
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Protagonist Therapeutics (NASDAQ:PTGX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Protagonist Therapeutics (NASDAQ:PTGX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024